




UK Standards for Microbiology Investigations

Review of users' comments received by Working group for microbiology standards in clinical bacteriology

B 11 Investigation of swabs from skin and superficial soft tissue infections



NICE has accredited the process used by Public Health England to produce Standards for Microbiology Investigations. Accreditation is valid for 5 years from July 2011. More information on accreditation can be viewed at www.nice.org.uk/accreditation.

Il details on our accreditation visit: www.nice.org.uk/accreditation

Recommendations are listed as ACCEPT/ PARTIAL ACCEPT/DEFER/ NONE or PENDING Issued by the Standards Unit, Microbiology Services, PHE Page: 1 of 9 RUC | B 11 | Issue no: 2 | Issue date: 04.05.16

1st Consultation: 06/01/2015 – 26/01/2015

Version of document consulted on: B 11dn+

Proposal for changes

Comment number	1			
Date received	06/01/2015	Lab name	Microbiology Queen Elizabeth Hospital	
Section	Introduction Pa	age 9		
Comment				
Erythrasma section, 3rc	l line 1st paragr	aph on page 'my mycotic' typo	error.	
Financial barriers				
N/A				
Health benefits				
No.				
Recommended	ACCEPT			
action Text updated.				

Comment number	2			
Date received	26/01/2015	Professional body	IBMS	
Section	a. Introduction	a. Introduction - Cellulitis and Erysipelas		
	b. Whole document			
	c. Introduction - Erythrasma			
	d. Section 4.6.1			
	e. Technical Information/Limitations – Specimen Containers			
	f. Section 4.7			
0				

Comment

- a. *Mycoplasma phocacerebrale* should be considered as a potential cause of cellulitis and/or adding to the animal bite section. This organism has been documented as the cause of cellulitis from animal bites in handlers of marine animals. There is a potential to confuse such infections with *Erysipelothrix* resulting in potential treatment failures (see evidence paper).
- b. Bacterial names need to be italicised throughout, not complete throughout the document.
- c. Under Erythrasma; 3 line

Erroneous text 'my' in sentence "plaques usually in the axillae and is often misdiagnosed as my mycotic infection."

d.	Line in table. If a yeast is significant in a site surely it should be identified, especially if treatment is to be given as antifungal break points are species specific.						
e.	Under the specimen containers section it mentions that CE marked leak proof containers should be used, but there is no reference to M40 complaint swabs (B11 and B14 only) despite stating that samples on swabs were acceptable for investigation. The CLSI M40-A2 Quality Control of Microbiological Transport Systems was revised in June 2014 and is the expected standard for transport swabs.						
f.	BSAC or EUCAST v	vhic	susceptibility testing each document make reference to th is fine for bacterial pathogens. However, for Candida and tioned in the text) only CLSI breakpoints apply.				
Ev	idence						
a.	http://www.ncbi.nlm.	.nih.	.gov/pubmed/21119845				
	www.bdmlr.org.uk/u	ploa	ads/documents/resources/bdmlr-seal-bites.doc				
Re	commended	a.	NONE				
ac	action		A literature search was carried out on Pubmed and18 references were identified regarding Seal finger. Of these two were case reports in English regarding <i>Mycoplasma phocacerebrale</i> . It was therefore agreed, that as this is rarely reported, it would not be included in the document.				
b. ACCEPT			ACCEPT				
			Text updated.				
		C.	ACCEPT				
			Text updated.				
		d.	ACCEPT				
	It was agreed that 'yeast' level was satisfactory as a minimum level of identification for yeast in this document. Further identification can be performed where clinically indicated. The fungal information in the introduction will be updated for consistency.						
		e.	NONE				
			CLSI M40 – A2 Quality control of microbiological transport systems is a quality standard not enforceable within the UK. The standard is for manufacturers and it is therefore outside of the scope of this document. The standard will therefore not be included in the SMIs.				
	f. NONE						
	Antimicrobial susceptibility break points for different species of yeast are available from EUCAST, however they are not required in this document as yeast are identified to yeast level only. Therefore a reference to CSLI will not be included in this SMI.						

2nd Consultation: 07/09/2015 – 05/10/2015

Version of document consulted on: B 11dw+ 07/09/2015 – 24/09/2015

B 11dy+ 25/09/2015 - 05/10/2015

Proposal for changes

Comment number	1			
Date received	08/09/2015	Lab name	Jersey General Hospital	
Section	AST 4.7.1	AST 4.7.1		
Comment				
It states that tetracycline vs S. <i>aureus</i> may be suppressed in children. Should tetracycline vs β haemolytic streptococci also follow this rule?				
Financial barriers				
Possible barriers from consultants who had traditionally more antimicrobial susceptibility testing options provided & to ensure that antibiotics reported ties with local policy.				
Recommended ACCEPT				
action Text in table updated.				

Comment number	2			
Date received	11/09/2015	Lab name	Salford Royal NHS Foundation Trust	
Section 4.7.1 Antimicrobial Susceptibility Testing and Reporting Table				
Comment				
a. S. aureus row - Penicillin: Only 10% susceptible is this really good use of a disc?				
b. S. aureus row - Clindamycin: Add co-trimoxazole				
c. Pyogenic Streptococci row - Clindamycin: Add linezolid?				
d. Enterobacteriaceae from surgical sites row - Amikacin: Add co-trimoxazole as oral				

- d. *Enterobacteriaceae* from surgical sites row Amikacin: Add co-trimoxazole as oral option
- e. *Enterobacteriaceae* from surgical sites row Ciprofloxacin: Move to first line (as betalactam allergy option)
- f. Enterobacteriaceae from surgical sites row Cefotaxime: Should this be cefoxitin?
- g. *Enterobacteriaceae* from sites prone to colonisation (eg ulcers) row Ampicillin: Add co-trimoxazole as oral option
- h. *Enterobacteriaceae* from sites prone to colonisation (eg ulcers) row Ciprofloxacin: Move to first line (as option for penicillin allergy)
- i. Enterobacteriaceae from sites prone to colonisation (eg ulcers) row Cefotaxime:

Should this be cefox	Should this be cefoxitin?			
j. Pseudomonads row	- C	efuroxime: Unlikely to be active vs Pseudomonads		
Recommended		ACCEPT		
action		Penicillin moved to the primary testing panel.		
	b.	ACCEPT		
		Co-trimoxazole has been added to the primary testing panel.		
	C.	ACCEPT		
		Linezolid has been added to the primary testing panel.		
	d.	ACCEPT		
		Co-trimoxazole was included, in the second version of the document to go for consultation, in the supplementary testing panel.		
	e.	NONE		
		It was agreed that ciprofloxacin should remain in the supplementary testing panel.		
	f.	NONE		
		Cefoxitin is used infrequently in the UK. Note 6 regarding AmpC removed.		
	g.	ACCEPT		
		Co-trimoxazole added to the supplementary testing panel.		
	h.	NONE		
e .		It was agreed that ciprofloxacin should remain in the supplementary testing panel.		
	i.	NONE		
		Cefoxitin is used infrequently in the UK. Note 6 regarding AmpC removed.		
	j.	ACCEPT		
		This was included in error and was removed from the second version of the document that went for consultation.		

Comment number	3				
Date received	14/09/2015	Lab name	Professional		
Section	Page 12 & 15				
Comment					
Typos:					
a. Page 12: Furuncles instead of foruncles.					
b. Page 15: Prevotella instead of prerevoltella.					

RUC | B 11 | Issue no: 2 | Issue date: 04.05.16

Recommended	a. ACCEPT
action	Text updated.
	b. ACCEPT
	Text updated.

Comment number	4				
	4				
Date received	24/09/2015	Lab name	NHS Highland- Oban Laboratory		
Section	4.7.1				
Comment					
	•	Cefotaxime as indicator of Am specific differentiation of AmpC			
Financial barriers	Financial barriers				
No.					
Health benefits					
No.	No.				
Recommended	PARTIAL ACCEPT				
action	It was agreed that cefoxitin is a better antibiotic for use as an indicator of AmpC production. However, cefoxitin is used infrequently in the UK and therefore Note 6 regarding AmpC has been removed.				

Targeted questions:

Do you agree with the concept of including antimicrobial susceptibility testing and reporting tables in SMIs?			
Date received	Lab name	Comment	
08/09/2015	Jersey General Hospital	Yes - if the data is generated by a reputable source ie EUCAST and does not contradict what the sources website/other literature state then that's helpful to me.	
14/09/2015	Professional	Yes.	
24/09/2015	NHS Highland- Oban Laboratory	Yes.	

Do you agree with the content of the antimicrobial susceptibility testing and reporting table in this SMI?

Date received	Lab name	Comment		
08/09/2015	Jersey General Hospital	Yes.		
14/09/2015	Professional	Yes.		
24/09/2015	NHS Highland- Oban Laboratory	Add temocilin for potential identification of CPE producers?		

Comments received outside of consultation

Comment number 1					
Date received	eceived 02/02/2015 Professional body ACOM				
Section	Various	1			
Comment					
Under consultation of	locument				
a. Introduction					
Fungal infections a dermatophytes he	•	very common! Suggest you a	dd at least		
b. Mycetoma page 1	l				
Change mould to r	noulds.				
c. Ulcers page 13					
	Please add viral infections, dermatological conditions (lichen) and autoimmune conditions (pemphigus/pemphgoid).				
d. Bite wounds page	15				
Add 'and Strep and	Add 'and Strep anginosus group' to 'a-haemolytic streptococci'.				
e. Section 4.5.1	e. Section 4.5.1				
Add fungi to the ta	ble and the flowo	chart.			
f. Section 4.5.1	. Section 4.5.1				
Fastidious organis	Fastidious organisms: oral streps and anaerobes.				
g. Section 4.6.1	. Section 4.6.1				
Moulds need to be added.					
Under review document					
h. Introduction					

RUC | B 11 | Issue no: 2 | Issue date: 04.05.16

Need to add the main fungal pathogens (such as dermatophytes, Candida).

i. Superficial mycoses page 12

Need to add mould infections of the nails.

j. Other skin infections page 13

Should systemic bacterial infections be mentioned (eg meningococcal sepsis) as systemic mycoses are?

k. Section 4.5.3

Haemophilus species: Oral streps and anaerobes missing.

I. Section 4.5.3

Fungi: Yeasts, moulds and dermatophytes? Other targets are given genus/species level. Would be helpful to expand "fungi".

Recommended	a.	PARTIAL ACCEPT
		Link to the dermatophyte SMI added to the scope.
	b.	ACCEPT
		Text updated.
	c.	PARTIAL ACCEPT
		Viral infections, dermatological conditions (lichen) are outside of the scope of the document. Text updated to include pemphigus/pemphgoid.
	d.	ACCEPT
		Streptococcus angiosus group added to the list or organisms.
	e.	NONE
		It was agreed that fungi would not be added to the flowchart, yeasts and moulds are included in the table. The list of organisms is not comprehensive, only the most common organisms isolated are included.
	f.	NONE
	g.	It was felt the fastidious organisms (oral streptococci and anaerobes) were already sufficiently covered in B4 - Investigation of mouth swabs and did not need to be added to this document. ACCEPT
		Table updated to include moulds.
	h.	ACCEPT
		Fungal infections included throughout introduction.
	i.	PARTIAL ACCEPT
		Text updated and link to B 39 - Investigation of dermatological specimens for superficial mycosis included.
		NONE

	It was felt that oral streptococci and anaerobes were already sufficiently covered in B4 - Investigation of mouth swabs and did not need to be added to this document.
k.	PARTIAL ACCEPT
	It was agreed that mould should be identified to 'genus' level and yeasts to 'yeast' level.
I.	PARTIAL ACCEPT
	Systemic bacterial infections in relation to <i>Mycobacterium</i> species infection and burns patients included.

Respondents indicating they were happy with the contents of the document

Overall number of comments: 5					
Date received	15/01/2015	Lab name	Nottingham University Hospitals		
Date received	21/01/2015	Lab name	Northern Health and Social Care Trust		
Date received	23/01/2015	Lab name	Truro		
Date received	14/09/2015	Lab name	Microbiology, Northern Health and Social Care Trust		
Date received	02/10/2015	Lab name	Microbiology at Hairmyres Hospital		